CareLit · DOI-Nachweis · Zeitschrift für Gastroenterologie
Integrated safety analysis of Sofosbuvir-based HCV treatment regimens from phase 3 studies
DOI 10.1055/s-0034-1386155
Bibliografische Angaben
Nachweis in CareLit
Autor:innenS Christensen, S Zeuzem, C Eisenbach, N Grüner, R Heyne, H Hinrichsen, D Hüppe, J Petersen, U Spengler, J Schulze-zur-Wiesch, D Häussinger, M Rössle, T Berg, D Brainard, W Symonds, J McHutchison, L Gallo, T Warger, N Forestier, MP Manns
ZeitschriftZeitschrift für Gastroenterologie
Ausgabe08/2014
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Background and aims: Sofosbuvir (SOF) is an HCV NS5B polymerase inhibitor that has demonstrated high sustained response rates in patients with genotypes 1 – 6 HCV infection. The aim of this analysis was to evaluate the combined safety across the SOF phase 3 studies. Methods: Safety data from patients enrolled in five Phase 3 studies (FISSION, FUSION, POSITRON, VALENCE and NEUTRINO) were reviewed. Adverse events (AEs…
Zitieren
Zitierempfehlung
S Christensen, S Zeuzem, C Eisenbach, N Grüner, R Heyne, H Hinrichsen, D Hüppe, J Petersen, U Spengler, J Schulze-zur-Wiesch, D Häussinger, M Rössle, T Berg, D Brainard, W Symonds, J McHutchison, L Gallo, T Warger, N Forestier, MP Manns (2014) Integrated safety analysis of Sofosbuvir-based HCV treatment regimens from phase 3 studies. Zeitschrift für Gastroenterologie (08). https://doi.org/10.1055/s-0034-1386155
Mit CareLit weiterarbeiten